世界の顕性肝性脳症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Overt Hepatic Encephalopathy Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4387 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、顕性肝性脳症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（タイプA（急性肝不全）、タイプB（肝疾患のない門脈全身バイパス）、タイプC（肝硬変））、用途別市場規模（病院、研究機関、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・顕性肝性脳症の市場動向 ・企業の競争状況、市場シェア ・顕性肝性脳症の種類別市場規模（タイプA（急性肝不全）、タイプB（肝疾患のない門脈全身バイパス）、タイプC（肝硬変）） ・顕性肝性脳症の用途別市場規模（病院、研究機関、診療所、その他） ・顕性肝性脳症の北米市場規模2016-2027（アメリカ、カナダ） ・顕性肝性脳症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・顕性肝性脳症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・顕性肝性脳症の中南米市場規模2016-2027（メキシコ、ブラジル） ・顕性肝性脳症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Alfa Wassermann、Cosmo Pharmaceuticals、Horizon Pharma、KannaLife Sciences、Ocer Therapeutics、Rebiotix、Spherium Biomed、Umecrine Cognition、ASKA Pharmaceutical、Mallinckrodt、Valeant） ・結論

Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.
Overt hepatic encephalopathy develops in approximately 40% of patients with cirrhosis during their clinical care. A first episode of overtencephalopathy predicts recurrence in 40% of patients. Aggravating factors for the development of hepatic encephalopathy in advanced liver disease include infection, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. Genetic abnormalities affecting ammonia metabolism can also play a role.

Market Analysis and Insights: Global Overt Hepatic Encephalopathy Market
The global Overt Hepatic Encephalopathy market size is projected to reach US$ 75 million by 2026, from US$ 49 million in 2019, at a CAGR of 6.4% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Overt Hepatic Encephalopathy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Overt Hepatic Encephalopathy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Overt Hepatic Encephalopathy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Overt Hepatic Encephalopathy market.

Global Overt Hepatic Encephalopathy Scope and Market Size
Overt Hepatic Encephalopathy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Overt Hepatic Encephalopathy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Type A (Acute Liver Failure)
Type B (Portal Systemic Bypass Without Liver Disease)
Type C (Liver Cirrhosis)

Segment by Application
Hospitals
Research Institutes
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Alfa Wassermann
Cosmo Pharmaceuticals
Horizon Pharma
KannaLife Sciences
Ocer Therapeutics
Rebiotix
Spherium Biomed
Umecrine Cognition
ASKA Pharmaceutical

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Overt Hepatic Encephalopathy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Type A (Acute Liver Failure)
1.2.3 Type B (Portal Systemic Bypass Without Liver Disease)
1.2.4 Type C (Liver Cirrhosis)
1.3 Market by Application
1.3.1 Global Overt Hepatic Encephalopathy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Research Institutes
1.3.4 Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Overt Hepatic Encephalopathy Market Perspective (2016-2027)
2.2 Overt Hepatic Encephalopathy Growth Trends by Regions
2.2.1 Overt Hepatic Encephalopathy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Overt Hepatic Encephalopathy Historic Market Share by Regions (2016-2021)
2.2.3 Overt Hepatic Encephalopathy Forecasted Market Size by Regions (2022-2027)
2.3 Overt Hepatic Encephalopathy Industry Dynamic
2.3.1 Overt Hepatic Encephalopathy Market Trends
2.3.2 Overt Hepatic Encephalopathy Market Drivers
2.3.3 Overt Hepatic Encephalopathy Market Challenges
2.3.4 Overt Hepatic Encephalopathy Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Overt Hepatic Encephalopathy Players by Revenue
3.1.1 Global Top Overt Hepatic Encephalopathy Players by Revenue (2016-2021)
3.1.2 Global Overt Hepatic Encephalopathy Revenue Market Share by Players (2016-2021)
3.2 Global Overt Hepatic Encephalopathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Overt Hepatic Encephalopathy Revenue
3.4 Global Overt Hepatic Encephalopathy Market Concentration Ratio
3.4.1 Global Overt Hepatic Encephalopathy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Overt Hepatic Encephalopathy Revenue in 2020
3.5 Overt Hepatic Encephalopathy Key Players Head office and Area Served
3.6 Key Players Overt Hepatic Encephalopathy Product Solution and Service
3.7 Date of Enter into Overt Hepatic Encephalopathy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Overt Hepatic Encephalopathy Breakdown Data by Type
4.1 Global Overt Hepatic Encephalopathy Historic Market Size by Type (2016-2021)
4.2 Global Overt Hepatic Encephalopathy Forecasted Market Size by Type (2022-2027)

5 Overt Hepatic Encephalopathy Breakdown Data by Application
5.1 Global Overt Hepatic Encephalopathy Historic Market Size by Application (2016-2021)
5.2 Global Overt Hepatic Encephalopathy Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Overt Hepatic Encephalopathy Market Size (2016-2027)
6.2 North America Overt Hepatic Encephalopathy Market Size by Type
6.2.1 North America Overt Hepatic Encephalopathy Market Size by Type (2016-2021)
6.2.2 North America Overt Hepatic Encephalopathy Market Size by Type (2022-2027)
6.2.3 North America Overt Hepatic Encephalopathy Market Size by Type (2016-2027)
6.3 North America Overt Hepatic Encephalopathy Market Size by Application
6.3.1 North America Overt Hepatic Encephalopathy Market Size by Application (2016-2021)
6.3.2 North America Overt Hepatic Encephalopathy Market Size by Application (2022-2027)
6.3.3 North America Overt Hepatic Encephalopathy Market Size by Application (2016-2027)
6.4 North America Overt Hepatic Encephalopathy Market Size by Country
6.4.1 North America Overt Hepatic Encephalopathy Market Size by Country (2016-2021)
6.4.2 North America Overt Hepatic Encephalopathy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Overt Hepatic Encephalopathy Market Size (2016-2027)
7.2 Europe Overt Hepatic Encephalopathy Market Size by Type
7.2.1 Europe Overt Hepatic Encephalopathy Market Size by Type (2016-2021)
7.2.2 Europe Overt Hepatic Encephalopathy Market Size by Type (2022-2027)
7.2.3 Europe Overt Hepatic Encephalopathy Market Size by Type (2016-2027)
7.3 Europe Overt Hepatic Encephalopathy Market Size by Application
7.3.1 Europe Overt Hepatic Encephalopathy Market Size by Application (2016-2021)
7.3.2 Europe Overt Hepatic Encephalopathy Market Size by Application (2022-2027)
7.3.3 Europe Overt Hepatic Encephalopathy Market Size by Application (2016-2027)
7.4 Europe Overt Hepatic Encephalopathy Market Size by Country
7.4.1 Europe Overt Hepatic Encephalopathy Market Size by Country (2016-2021)
7.4.2 Europe Overt Hepatic Encephalopathy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Overt Hepatic Encephalopathy Market Size (2016-2027)
8.2 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Type
8.2.1 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Type (2016-2027)
8.3 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Application
8.3.1 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Application (2016-2027)
8.4 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Region
8.4.1 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Overt Hepatic Encephalopathy Market Size (2016-2027)
9.2 Latin America Overt Hepatic Encephalopathy Market Size by Type
9.2.1 Latin America Overt Hepatic Encephalopathy Market Size by Type (2016-2021)
9.2.2 Latin America Overt Hepatic Encephalopathy Market Size by Type (2022-2027)
9.2.3 Latin America Overt Hepatic Encephalopathy Market Size by Type (2016-2027)
9.3 Latin America Overt Hepatic Encephalopathy Market Size by Application
9.3.1 Latin America Overt Hepatic Encephalopathy Market Size by Application (2016-2021)
9.3.2 Latin America Overt Hepatic Encephalopathy Market Size by Application (2022-2027)
9.3.3 Latin America Overt Hepatic Encephalopathy Market Size by Application (2016-2027)
9.4 Latin America Overt Hepatic Encephalopathy Market Size by Country
9.4.1 Latin America Overt Hepatic Encephalopathy Market Size by Country (2016-2021)
9.4.2 Latin America Overt Hepatic Encephalopathy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Overt Hepatic Encephalopathy Market Size (2016-2027)
10.2 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Type
10.2.1 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Type (2016-2027)
10.3 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Application
10.3.1 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Application (2016-2027)
10.4 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Country
10.4.1 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Alfa Wassermann
11.1.1 Alfa Wassermann Company Details
11.1.2 Alfa Wassermann Business Overview
11.1.3 Alfa Wassermann Overt Hepatic Encephalopathy Introduction
11.1.4 Alfa Wassermann Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.1.5 Alfa Wassermann Recent Development
11.2 Cosmo Pharmaceuticals
11.2.1 Cosmo Pharmaceuticals Company Details
11.2.2 Cosmo Pharmaceuticals Business Overview
11.2.3 Cosmo Pharmaceuticals Overt Hepatic Encephalopathy Introduction
11.2.4 Cosmo Pharmaceuticals Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.2.5 Cosmo Pharmaceuticals Recent Development
11.3 Horizon Pharma
11.3.1 Horizon Pharma Company Details
11.3.2 Horizon Pharma Business Overview
11.3.3 Horizon Pharma Overt Hepatic Encephalopathy Introduction
11.3.4 Horizon Pharma Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.3.5 Horizon Pharma Recent Development
11.4 KannaLife Sciences
11.4.1 KannaLife Sciences Company Details
11.4.2 KannaLife Sciences Business Overview
11.4.3 KannaLife Sciences Overt Hepatic Encephalopathy Introduction
11.4.4 KannaLife Sciences Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.4.5 KannaLife Sciences Recent Development
11.5 Ocer Therapeutics
11.5.1 Ocer Therapeutics Company Details
11.5.2 Ocer Therapeutics Business Overview
11.5.3 Ocer Therapeutics Overt Hepatic Encephalopathy Introduction
11.5.4 Ocer Therapeutics Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.5.5 Ocer Therapeutics Recent Development
11.6 Rebiotix
11.6.1 Rebiotix Company Details
11.6.2 Rebiotix Business Overview
11.6.3 Rebiotix Overt Hepatic Encephalopathy Introduction
11.6.4 Rebiotix Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.6.5 Rebiotix Recent Development
11.7 Spherium Biomed
11.7.1 Spherium Biomed Company Details
11.7.2 Spherium Biomed Business Overview
11.7.3 Spherium Biomed Overt Hepatic Encephalopathy Introduction
11.7.4 Spherium Biomed Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.7.5 Spherium Biomed Recent Development
11.8 Umecrine Cognition
11.8.1 Umecrine Cognition Company Details
11.8.2 Umecrine Cognition Business Overview
11.8.3 Umecrine Cognition Overt Hepatic Encephalopathy Introduction
11.8.4 Umecrine Cognition Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.8.5 Umecrine Cognition Recent Development
11.9 ASKA Pharmaceutical
11.9.1 ASKA Pharmaceutical Company Details
11.9.2 ASKA Pharmaceutical Business Overview
11.9.3 ASKA Pharmaceutical Overt Hepatic Encephalopathy Introduction
11.9.4 ASKA Pharmaceutical Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.9.5 ASKA Pharmaceutical Recent Development
11.10 Mallinckrodt
11.10.1 Mallinckrodt Company Details
11.10.2 Mallinckrodt Business Overview
11.10.3 Mallinckrodt Overt Hepatic Encephalopathy Introduction
11.10.4 Mallinckrodt Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.10.5 Mallinckrodt Recent Development
11.11 Valeant
11.11.1 Valeant Company Details
11.11.2 Valeant Business Overview
11.11.3 Valeant Overt Hepatic Encephalopathy Introduction
11.11.4 Valeant Revenue in Overt Hepatic Encephalopathy Business (2016-2021)
11.11.5 Valeant Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Overt Hepatic Encephalopathy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Type A (Acute Liver Failure)
Table 3. Key Players of Type B (Portal Systemic Bypass Without Liver Disease)
Table 4. Key Players of Type C (Liver Cirrhosis)
Table 5. Global Overt Hepatic Encephalopathy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Overt Hepatic Encephalopathy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Overt Hepatic Encephalopathy Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Overt Hepatic Encephalopathy Market Share by Regions (2016-2021)
Table 9. Global Overt Hepatic Encephalopathy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Overt Hepatic Encephalopathy Market Share by Regions (2022-2027)
Table 11. Overt Hepatic Encephalopathy Market Trends
Table 12. Overt Hepatic Encephalopathy Market Drivers
Table 13. Overt Hepatic Encephalopathy Market Challenges
Table 14. Overt Hepatic Encephalopathy Market Restraints
Table 15. Global Overt Hepatic Encephalopathy Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Overt Hepatic Encephalopathy Market Share by Players (2016-2021)
Table 17. Global Top Overt Hepatic Encephalopathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overt Hepatic Encephalopathy as of 2020)
Table 18. Ranking of Global Top Overt Hepatic Encephalopathy Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Overt Hepatic Encephalopathy Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Overt Hepatic Encephalopathy Product Solution and Service
Table 22. Date of Enter into Overt Hepatic Encephalopathy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Overt Hepatic Encephalopathy Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Overt Hepatic Encephalopathy Revenue Market Share by Type (2016-2021)
Table 26. Global Overt Hepatic Encephalopathy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Overt Hepatic Encephalopathy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Overt Hepatic Encephalopathy Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Overt Hepatic Encephalopathy Revenue Market Share by Application (2016-2021)
Table 30. Global Overt Hepatic Encephalopathy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Overt Hepatic Encephalopathy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Overt Hepatic Encephalopathy Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Overt Hepatic Encephalopathy Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Overt Hepatic Encephalopathy Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Overt Hepatic Encephalopathy Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Overt Hepatic Encephalopathy Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Overt Hepatic Encephalopathy Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Overt Hepatic Encephalopathy Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Overt Hepatic Encephalopathy Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Overt Hepatic Encephalopathy Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Overt Hepatic Encephalopathy Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Overt Hepatic Encephalopathy Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Overt Hepatic Encephalopathy Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Overt Hepatic Encephalopathy Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Overt Hepatic Encephalopathy Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Overt Hepatic Encephalopathy Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Overt Hepatic Encephalopathy Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Overt Hepatic Encephalopathy Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Overt Hepatic Encephalopathy Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Overt Hepatic Encephalopathy Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Overt Hepatic Encephalopathy Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Overt Hepatic Encephalopathy Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Overt Hepatic Encephalopathy Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Overt Hepatic Encephalopathy Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Overt Hepatic Encephalopathy Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Overt Hepatic Encephalopathy Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Overt Hepatic Encephalopathy Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Overt Hepatic Encephalopathy Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Overt Hepatic Encephalopathy Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Overt Hepatic Encephalopathy Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Overt Hepatic Encephalopathy Market Size by Country (2022-2027) & (US$ Million)
Table 62. Alfa Wassermann Company Details
Table 63. Alfa Wassermann Business Overview
Table 64. Alfa Wassermann Overt Hepatic Encephalopathy Product
Table 65. Alfa Wassermann Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 66. Alfa Wassermann Recent Development
Table 67. Cosmo Pharmaceuticals Company Details
Table 68. Cosmo Pharmaceuticals Business Overview
Table 69. Cosmo Pharmaceuticals Overt Hepatic Encephalopathy Product
Table 70. Cosmo Pharmaceuticals Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 71. Cosmo Pharmaceuticals Recent Development
Table 72. Horizon Pharma Company Details
Table 73. Horizon Pharma Business Overview
Table 74. Horizon Pharma Overt Hepatic Encephalopathy Product
Table 75. Horizon Pharma Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 76. Horizon Pharma Recent Development
Table 77. KannaLife Sciences Company Details
Table 78. KannaLife Sciences Business Overview
Table 79. KannaLife Sciences Overt Hepatic Encephalopathy Product
Table 80. KannaLife Sciences Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 81. KannaLife Sciences Recent Development
Table 82. Ocer Therapeutics Company Details
Table 83. Ocer Therapeutics Business Overview
Table 84. Ocer Therapeutics Overt Hepatic Encephalopathy Product
Table 85. Ocer Therapeutics Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 86. Ocer Therapeutics Recent Development
Table 87. Rebiotix Company Details
Table 88. Rebiotix Business Overview
Table 89. Rebiotix Overt Hepatic Encephalopathy Product
Table 90. Rebiotix Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 91. Rebiotix Recent Development
Table 92. Spherium Biomed Company Details
Table 93. Spherium Biomed Business Overview
Table 94. Spherium Biomed Overt Hepatic Encephalopathy Product
Table 95. Spherium Biomed Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 96. Spherium Biomed Recent Development
Table 97. Umecrine Cognition Company Details
Table 98. Umecrine Cognition Business Overview
Table 99. Umecrine Cognition Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 100. Umecrine Cognition Recent Development
Table 101. ASKA Pharmaceutical Company Details
Table 102. ASKA Pharmaceutical Business Overview
Table 103. ASKA Pharmaceutical Overt Hepatic Encephalopathy Product
Table 104. ASKA Pharmaceutical Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 105. ASKA Pharmaceutical Recent Development
Table 106. Mallinckrodt Company Details
Table 107. Mallinckrodt Business Overview
Table 108. Mallinckrodt Overt Hepatic Encephalopathy Product
Table 109. Mallinckrodt Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 110. Mallinckrodt Recent Development
Table 111. Valeant Company Details
Table 112. Valeant Business Overview
Table 113. Valeant Overt Hepatic Encephalopathy Product
Table 114. Valeant Revenue in Overt Hepatic Encephalopathy Business (2016-2021) & (US$ Million)
Table 115. Valeant Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Overt Hepatic Encephalopathy Market Share by Type: 2020 VS 2027
Figure 2. Type A (Acute Liver Failure) Features
Figure 3. Type B (Portal Systemic Bypass Without Liver Disease) Features
Figure 4. Type C (Liver Cirrhosis) Features
Figure 5. Global Overt Hepatic Encephalopathy Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Research Institutes Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Overt Hepatic Encephalopathy Report Years Considered
Figure 11. Global Overt Hepatic Encephalopathy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Overt Hepatic Encephalopathy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Overt Hepatic Encephalopathy Market Share by Regions: 2020 VS 2027
Figure 14. Global Overt Hepatic Encephalopathy Market Share by Regions (2022-2027)
Figure 15. Global Overt Hepatic Encephalopathy Market Share by Players in 2020
Figure 16. Global Top Overt Hepatic Encephalopathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overt Hepatic Encephalopathy as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Overt Hepatic Encephalopathy Revenue in 2020
Figure 18. Global Overt Hepatic Encephalopathy Revenue Market Share by Type (2016-2021)
Figure 19. Global Overt Hepatic Encephalopathy Revenue Market Share by Type (2022-2027)
Figure 20. North America Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Overt Hepatic Encephalopathy Market Share by Type (2016-2027)
Figure 22. North America Overt Hepatic Encephalopathy Market Share by Application (2016-2027)
Figure 23. North America Overt Hepatic Encephalopathy Market Share by Country (2016-2027)
Figure 24. United States Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Overt Hepatic Encephalopathy Market Share by Type (2016-2027)
Figure 28. Europe Overt Hepatic Encephalopathy Market Share by Application (2016-2027)
Figure 29. Europe Overt Hepatic Encephalopathy Market Share by Country (2016-2027)
Figure 30. Germany Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Overt Hepatic Encephalopathy Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Overt Hepatic Encephalopathy Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Overt Hepatic Encephalopathy Market Share by Region (2016-2027)
Figure 40. China Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Overt Hepatic Encephalopathy Market Share by Type (2016-2027)
Figure 48. Latin America Overt Hepatic Encephalopathy Market Share by Application (2016-2027)
Figure 49. Latin America Overt Hepatic Encephalopathy Market Share by Country (2016-2027)
Figure 50. Mexico Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Overt Hepatic Encephalopathy Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Overt Hepatic Encephalopathy Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Overt Hepatic Encephalopathy Market Share by Country (2016-2027)
Figure 56. Turkey Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Overt Hepatic Encephalopathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Alfa Wassermann Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 60. Cosmo Pharmaceuticals Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 61. Horizon Pharma Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 62. KannaLife Sciences Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 63. Ocer Therapeutics Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 64. Rebiotix Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 65. Spherium Biomed Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 66. Umecrine Cognition Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 67. ASKA Pharmaceutical Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 68. Mallinckrodt Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 69. Valeant Revenue Growth Rate in Overt Hepatic Encephalopathy Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---